• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1990 Fiscal Year Final Research Report Summary

Development of [ ^<18>F]-Synthons and Application to Dopamine D-2 Receptor Ligands

Research Project

Project/Area Number 01470134
Research Category

Grant-in-Aid for General Scientific Research (B)

Allocation TypeSingle-year Grants
Research Field Radiation science
Research InstitutionKyushu University

Principal Investigator

MAEDA Minoru  Kyushu University Faculty of Pharmaceutical Sciences, Professor, 薬学部, 教授 (70101178)

Project Period (FY) 1989 – 1990
Keywordsdopamine receptor / fluorine-18 / benzamide / rat distribution / antagonist / radiopharmaceutical / in vivo binding
Research Abstract

A series of eticlopride [(-) - (S) -5-chloro-3-ethyl-N- [(1-ethyl-2-pyrrolidinyl) methyl] -6-methoxysalicylamide] derivatives bearing pyrrolidino N-fluoroethyl, N-fluoropropyl, N-p-fluorobenzyl or substituted with fluorine at the 4-position of the pyrrolidine moiety (FP-eticlopride) were synthesized and evaluated as potential dopaminergic receptor-based positron tomography radiopharmaceuticals. Radiosynthetic procedures for producing these F-18 labeled analogs by F-18 fluoride displacement of the sulfonate esters were also developed. In vitro binding assays using competitive displacement of H-3 spiperone from rat striatal tissue indicated that IC_<50> values of the N-fluoroalkyl derivatives of eticlopride were 17-23 nM, whereas the corresponding value for FP-eticlopride was 1.9 nM, approximately equal to that of eticlopride itself (IC_<50> 2.9 nM). The decreased Dopamine D-2 bindingaffinity of N-fluoroalkylated derivatives of eticlopride relative to eticlopride was corroborated by in vivo tissue biodistribution results in rats, as reflected by the low striatum to cerebellum ratios for these compounds. The regional distribution of F-18 labeled FP-eticlopride in rat showed a localization associated with D-2 receptors. In vivo uptake in the rat striatum was 0.56 %dose/g at 30 min and 0.47 %dose/g at 90 min after injection. The striatum-cerebellum ratio was strongly increasing with time and reached value of 5.1 at 90 min. Uptake in the striatum was blocked by pretreatment with known D-2 antagonist haloperidol (80% decrease of in vivo binding). In vivo defluorination took place to a significant degree over the 90 min-interval.

  • Research Products

    (4 results)

All Other

All Publications (4 results)

  • [Publications] 福村 利光,堂本 英樹,前田 稔, 福沢 絵津子,小嶋 正治: "Synthesis and in Vitro Affinity for Dopamine Dー2 Receptor of NーFluorineーSubstituted Analogs of Eticlopride" Chem.Pharm.Bull.38. 1740-1742 (1990)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 福村 利光,前田 稔,一矢 有一,桑原 康雄,大塚 誠,田原 隆,増田 康治,小嶋 正治: "エチクロプライドの^<18>Fーフルオロアルキル誘導体の合成" 核医学. 26. 1042 (1989)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] T. Fukumura, H. Dohmoto, M. Maeda, E. Fukuzawa and M. Kojima: "Synthesis and in Vitro Affinity for Dopamine D-2 Receptor of N-Fluorine-Substituted Analogs of Eticlopride" Chem. Pharm. Bull.38(6). 1740-1742 (1990)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] T. Fukumura, M. Maeda, Y. Ichiya, Y. Kuwabara, M. Otsuka, T. Tawara and K. Masuda: "Synthesis of Flourine-18 Labeled N-Fluoroalkylated Analogs of Eticlopride" Jap. J. Nucl. Med.26(8). 1042 (1989)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 1993-08-12  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi